Man Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Man Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-406,344	Closed	-$471K	–	2516
2025 Q2	$471K	Buy	406,344 +305,328	+302%	+$403K	﹤0.01%	1847
2025 Q1	$161K	Buy	+101,016	New	+$218K	﹤0.01%	2064
2024 Q4	–	Sell	-54,459	Closed	-$200K	–	2238
2024 Q3	$200K	Buy	+54,459	New	+$198K	﹤0.01%	1861

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Man Group's ZNTL Position: Q3 2025 in Review

Man Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 406,344 shares — an estimated $471K sold.

Man Group first reported a position in ZNTL in Q3 2024 and held it in 3 quarters. The position peaked at $471K in Q2 2025. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

Man Group reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Man Group sold 406,344 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $471K.
Man Group first reported a position in Zentalis Pharmaceuticals in Q3 2024 and held it in 3 quarters.
Man Group's Zentalis Pharmaceuticals position peaked at $471K in Q2 2025.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Man Group's 13F filing for Q3 2025, filed 14 Nov 2025.